APD811 (ralinepag), a novel non-prostanoid IP receptor agonist, has potent antiproliferative and vasorelaxant properties in human pulmonary artery.

Shen L¹, Patel J¹, Norel X², Adams J³, Behan D³, Clapp LH¹
¹Institute of Cardiovascular Science, UCL, London UK
²INSERM U1148, CHU X. Bichat, Paris, France
³Arena Pharmaceuticals, Inc. San Diego, CA USA

Introduction: APD811 is an oral, non-prostanoid IP receptor agonist with a long plasma half-life (~24 hr) in development for pulmonary arterial hypertension (PAH). Little is known about the pulmonary pharmacology of this agent. The aim was to compare the functional effects of APD811 in distal human pulmonary smooth muscle cells (PASMCs) and arteries (PAs) alongside other prostacyclin mimetics already licensed for PAH.

Methods: PASMCs from PAH patients were grown in 9% serum and treated with IP receptor agonists ± 1 μM RO-1138452 (IP receptor antagonist) for 1hr (cyclic AMP) or 96hr (cell proliferation). Cyclic AMP was assessed using an ELISA and cell proliferation using an MTS assay. Distal PAs from control patients (mean age 66yr) were mounted in a myograph and pre-tensioned to an equivalent of ~22 mmHg (3K Pascal) before being constricted with U46619 (thromboxane mimetic; 100nM). The concentration (EC₅₀) producing the half maximal response (Emax) was determined.

Results: Iloprost, APD811, MRE-269 (selexipag metabolite) and treprostinil increased cyclic AMP (EC₅₀ 17, 252, 340, 550 nM, respectively). Eₘₐₓ was lower (P<0.001; n=5) for all three agents (64, 45, 25%, respectively) compared with treprostinil. In proliferation assays, APD811 was 10 fold more potent (14 nM) than MRE-269 (145 nM) and Eₘₐₓ were lower for both compared to treprostinil (57% versus 89%). RO-1138452 (1 μM) abolished agonist-induced cAMP generation and the antiproliferative effects of APD811 and MRE-269. In contrast, the antiproliferative effects of treprostinil and iloprost were weakly inhibited by RO-1138452. In PAs, APD811 produced a significantly (P<0.001, n=5–8) greater relaxation (Eₘₐₓ 98%) compared to iloprost (Eₘₐₓ 84%), treprostinil (Eₘₐₓ 71%) or MRE-296 (Eₘₐₓ 59%) and was more potent than MRE-269 (EC₅₀ 449nM versus 1579 nM) but similar to iloprost (EC₅₀ 650 nM) or treprostinil (EC₅₀=320 nM).

Conclusions: APD811 and MRE-269 behave as selective, but partial IP receptor agonists, whereas iloprost and treprostinil can inhibit cell proliferation through IP-receptor independent pathways. In all assays APD811 produced superior effects to MRE-269 and had a favourable vasodilator profile compared with iloprost and treprostinil.

Acknowledgement/Funding: Funding for this study was provided by Arena Pharmaceuticals, Inc.